- August 5, 2019
Alzheimer’s patients didn’t decline after getting a cocktail derived from young blood, but big questions remain
Alzheimer’s patients who received an experimental protein cocktail derived from young blood plasma maintained their performance on measures of cognition and function after six months, the biotech company behind the therapy, Alkahest, said on Monday.
- August 1, 2019
NeuBase takes antisense oligos to more targets in more places
Newcomer NeuBase Therapeutics is re-engineering antisense oligos to access a broader range of targets, while simultaneously solving the modality’s dosing and delivery issues. With three approvals since the start of 2016, antisense oligonucleotides (ASOs) have started to hit their stride, yet first-generation technologies are limited on multiple fronts.
- July 29, 2019
Oral AMD treatment meets phase 2 endpoints
At the American Society of Retina Specialists meeting, Michael Stewart, MD, chairman and professor of ophthalmology at the Mayo Clinic of Jacksonville, Florida, discusses phase 2 results of AKST4290 (Alkahest), an orally administered small molecule CCR3 inhibitor.
- July 29, 2019
Alkahest Phase 2a Study AKST4290-202 in Refractory Wet AMD Meets Primary and Secondary Endpoints
Alkahest announced that its phase 2a trial of AKST4290, an orally-administered small molecule CCR3 inhibitor, met the primary endpoint of achieving an increase in best corrected visual acuity (BCVA) in patients with refractory wet or neovascular age-related macular degeneration (nAMD). AKST4290 was also found to be safe and well-tolerated, meeting the secondary endpoint of the trial.
- July 25, 2019
Anthony Fiorino, MD, PhD: Using nVNS in Various Migraine Populations
At the 2019 American Headache Society Annual Meeting, July 11-14, in Philadelphia, Pennsylvania, one of the topics of focus among the newly approved therapies for migraine was the use of devices to treat the condition acutely. As such, a number of companies presented data on neuromodulation and neurostimulation devices—including electroCore, which has undergone the development of noninvasive vagus nerve stimulation (nVNS) to treat migraine, episodic cluster headache, and is currently being studied in post-traumatic headache.
- July 15, 2019
Oncocyte CEO, Ronnie Andrews On Developing New Ways To Test For Lung Cancer
Watch “Ronnie Andrews On Developing New Ways To Test For Lung Cancer”, an archived episode of The Watch List originally aired 07/15/2019 on the TD Ameritrade Network.
- July 12, 2019
Not just a vaccine company: How this Gaithersburg biotech CEO plans to grow the business
The Gaitherburg biotech’s CEO, not yet a year into his tenure, sees the prospect of more acquisitions or licensing deals going forward.
- July 12, 2019
Positive results of a prep-free colon cancer screening device reported
Check-Cap announced positive final results from its completed post-CE approval study evaluating the efficacy and safety of the C-Scan system. “The final results from the post-CE approval study confirm the potential clinical value of the C-Scan system. The results also demonstrate an advancement in the detection of larger polyps, generally considered to have higher potential for malignant transformation,” Nadir Arber, MD, MSc, MHA, director of the Integrated Cancer Prevention Center at the Tel-Aviv Sourasky Medical Center, said in a press release.
